Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
706,669

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 7:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Gilead's (GILD) CAR T Cell Therapy Gets Positive CHMP Opinion

Gilead (GILD) gets positive CHMP opinion for KTE-X19, a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma.

5 Big Pharma/Biotech Stocks Set to Trump Q3 Earnings Estimates

Let us take a look at some drug/biotech stocks including Glaxo (GSK) and Merck (MRK) that are poised to beat on earnings for the third quarter.

Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports third-quarter earnings.

Lilly to Acquire Private Biotech for Boosting Pain Portfolio

Lilly (LLY) inks a deal to acquire Disarm Therapeutics for an upfront payment of $135 million to strengthen its pain and neurological diseases portfolio.

Stock Market News for Oct 16, 2020

U.S. stock markets closed lower on Thursday as the fresh fiscal stimulus impasse continued.

Vertex (VRTX) is an Incredible Growth Stock: 3 Reasons Why

Vertex (VRTX) could produce exceptional returns because of its solid growth attributes.

Vertex to End Phase II Study on AAT Deficiency Candidate

Vertex (VRTX) to discontinue phase II study on VX-814 based on the liver enzyme elevations observed and the determination that it would be difficult to safely achieve targeted exposure levels.

Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $276.09, marking a +0.54% move from the previous day.

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

The Zacks Analyst Blog Highlights: Emergent BioSolutions, Vertex Pharmaceuticals, Editas Medicine, Cellectis and Thermo Fisher

Booming Gene Editing Market to Pep Up These 5 Biotech Stocks

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $265.82, marking a +1.85% move from the previous day.

Corbus Stock Down as Lenabasum Fails to Meet Primary Endpoint

Corbus (CRBP) releases disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis.

Alexion Plans to Raise 2020 Sales View, Buy Back $3B Shares

Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.

Sumit Singh headshot

Add These 5 Stocks With Impressive Interest Coverage Ratio

Interest Coverage Ratio is used to determine how effectively a company can pay the interest charges on its debt.

Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

The biotech sector remains in focus with regulatory and other pipeline updates.

Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $270.31, moving +0.96% from the previous trading session.

Vertex's Kalydeco Gets FDA Nod for Cystic Fibrosis in Infants

Vertex (VRTX) wins an FDA approval for Kalydeco to treat cystic fibrosis in infants aged four to less than six months with minimum one mutation in their CFTR gene that is responsive to Kalydeco.

CRISPR Therapeutics Gene Therapy CTX001 Gets PRIME Status

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals' CRISPR/Cas9 gene-editing therapy candidate, CTX001, gets Priority Medicines designation for treating sickle cell disease.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.52%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $264 in the latest trading session, marking a -0.52% move from the prior day.

Vertex Eyes Label Expansion of Triple Combo CF Drug in Europe

Vertex's (VRTX) label expansion application Kaftrio in combination with Kalydeco gets accepted for review by the European Medicines Agency.

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $257.96 in the latest trading session, marking a +0.9% move from the prior day.

Kevin Cook headshot

CRISPR Stocks: Buy or Trade?

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

J&J to Stop Development of Influenza Candidate Pimodivir

Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.